Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

• Autores principales: Ferenc Takács (Autor), Lili Kotmayer (Autor), Ágnes Czeti (Autor), Gábor Szalóki (Autor), Tamás László (Autor), Gábor Mikala (Autor), Ágnes Márk (Autor), András Masszi (Autor), Péter Farkas (Autor), Márk Plander (Autor), Júlia Weisinger (Autor), Judit Demeter (Autor), Sándor Fekete (Autor), László Szerafin (Autor), Beáta Margit Deák (Autor), Erika Szaleczky (Autor), Adrienn Sulák (Autor), Zita Borbényi (Autor), Gábor Barna (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to...